Showing results (11-20 of 8,734) with videos related to

Sort By:
Pageof 874
International Journal of Rheumatic Diseases|June 27, 2014
In vivo quantification of mouse autoimmune arthritis by PET/CTSmriti Kundu-Raychaudhuri, Anupam Mitra, Ananya Datta-Mitra, et al.
International Journal of Rheumatic Diseases|October 30, 2019
Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PETSanchita Raychaudhuri, Christine Abria, Zachary T Harmany, et al.
Clinical and Experimental Immunology|January 17, 2017
In-vivo quantitative assessment of the therapeutic response in a mouse model of collagen-induced arthritis using 18 F-fluorodeoxyglucose positron emission tomographyA Mitra, S Kundu-Raychaudhuri, C Abria, et al.
The Journal of Investigative Dermatology|January 15, 2013
1α,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT/mTOR signaling cascades: a therapeutic agent for psoriasisAnanya Datta Mitra, Siba P Raychaudhuri, Christine J Abria, et al.
Acute and Critical Care|June 12, 2024
Microbial infections in burn patientsSouvik Roy, Preeti Mukherjee, Sutrisha Kundu, et al.
Virus Research|August 19, 2003
The interaction of cytoplasmic RNA viruses with the nucleusMary K Weidman, Rahki Sharma, Santanu Raychaudhuri, et al.
The Journal of Investigative Dermatology|March 14, 2008
FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft modelSiba P Raychaudhuri, Smriti Kundu-Raychaudhuri, Kouichi Tamura, et al.
Systems and Synthetic Biology|March 5, 2014
Death ligand concentration and the membrane proximal signaling module regulate the type 1/type 2 choice in apoptotic death signalingSubhadip Raychaudhuri, Somkanya C Raychaudhuri
Cells|April 9, 2014
Monte carlo study elucidates the type 1/type 2 choice in apoptotic death signaling in healthy and cancer cellsSubhadip Raychaudhuri, Somkanya C Raychaudhuri
AIDS Research and Human Retroviruses|October 27, 2001
Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946)S Kundu-Raychaudhuri, A Sevin, P Kilgo, et al.
Pageof 874